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Abstract
Background—For decades, non-Hodgkin lymphoma (NHL) incidence has been increasing
worldwide. NHL risk is strongly increased among HIV-infected people. Our understanding of
trends in NHL incidence has been hampered by difficulties in separating HIV-infected NHL cases
from general population rates.
Materials and Methods—NHL incidence data during 1992–2009 were derived from 10 U.S.
SEER cancer registries with information on HIV status at NHL diagnosis. The CDC estimated the
number of people living with HIV in the registry areas. The proportion of NHL cases with HIV
and NHL rates in the total and the HIV-uninfected populations were estimated. Time trends were
assessed with Joinpoint analyses.
Results—Of 115,643 NHL cases diagnosed during 1992–2009, 5.9% were HIV-infected. The
proportions of NHL cases with HIV were highest for diffuse large B-cell (DLBCL; 7.8%), Burkitt
(26.9%), and peripheral T-cell lymphomas (3.2%) with low proportions (≤1.1%) in the other
subtypes. NHL rates in the total population increased 0.3% per year during 1992–2009. However,
rates of NHL in HIV-uninfected people increased 1.4% per year during 1992–2003, before
becoming stable through 2009. Similar trends were observed for DLBCL and follicular lymphoma
in HIV-uninfected people; rates increased 2.7% per year until 2003 and 1.7% per year until 2005,
respectively, before stabilizing.
Conclusions—NHL incidence rates in the U.S. have plateaued over the last 5–10 years,
independent of HIV infection.
Impact—Though the causes of the long-term increase in NHL incidence rates in the U.S. remain
unknown, general population rates of NHL have stabilized since the early 2000s, independent of
HIV.
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Notable increases in the incidence of non-Hodgkin lymphoma (NHL) have been
documented internationally throughout the second half of the twentieth century (1–6). In the
United States, rates more than tripled in that interval (7), with similar increases across age
groups and among men and women (1). Mortality rates from NHL also have increased,
suggesting that changes in NHL classification alone cannot account for increasing rates (7,
8). Although studies have identified etiologic factors that may have contributed to increasing
NHL rates, such as viruses, medical conditions and drugs, and occupational or
environmental exposures (9), most of the increase in NHL rates remains unexplained.
With the onset of the human immunodeficiency virus (HIV) epidemic in the U.S. in the
1980s, NHL rates increased more steeply than in previous decades as NHL cases in persons
with HIV were added to the longer-term increase in NHL incidence (10). Although HIV
prevalence in the U.S. was low, the associated NHL risks were very large (77-fold)
compared to the general population (11). The effect of HIV varies by NHL subtype, with
risks particularly increased for diffuse large B-cell lymphoma (DLBCL, 30-fold), Burkitt
lymphoma (50-fold) and central nervous system (CNS) lymphoma (1,020-fold) (12), three
types of NHL that are considered acquired immune deficiency syndrome (AIDS)-defining
events by the Centers for Disease Control and Prevention (CDC) (13). In 1996, highly active
antiretroviral therapy (HAART) was introduced to treat HIV infection, improving immune
function of persons with HIV and resulting in a 58% decline in NHL risk (12, 14). During
1980–2007, 5.5% of DLBCLs, 19.4% of Burkitt lymphomas and 26.2% of CNS lymphomas
in the U.S. occurred among HIV-infected individuals (15).
In recent years, NHL incidence rates appear to have plateaued, leading some studies to
suggest that the NHL epidemic has ended (3, 6, 16, 17). However, previous studies of NHL
rates have not separated HIV-infected NHL cases from total NHL rates. To assess whether
the long-standing epidemic of NHL in the general population has ended, we combined data
from the Surveillance, Epidemiology and End Results (SEER) Program and the CDC from
1992–2009, enabling us to quantify the proportion of NHL cases with HIV infection and
estimate NHL incidence rates over time in the absence of HIV-infected NHL cases.
Materials and Methods
Data sources
NHL incidence data were derived from 10 U.S. SEER population-based cancer registries
that ascertained cancer diagnoses during 1992– 2009 (Connecticut, Hawaii, New Mexico,
Utah, Atlanta, Detroit, Seattle/Puget Sound, Los Angeles, San Francisco/Oakland, San Jose/
Monterey) and collected information on HIV status from medical records at the time of
NHL diagnosis (18, 19). A previous study documented high sensitivity of the SEER HIV
indicator, despite a large proportion of NHL cases with an unknown HIV status (19). We
therefore classified the 71% of cases with unknown HIV status as HIV-uninfected. In a
sensitivity analysis, we re-classified NHL cases as HIV-infected if they had HIV listed as
the cause of death, but did not have a positive HIV indicator (n=581, 0.5%).
Because NHL is comprised of a heterogeneous group of distinct subtypes, we examined
NHL overall and by subtype. NHLs were identified using the SEER site recode variable
based on morphology codes from the International Classification of Diseases for Oncology,
third edition (ICD-O-3) (20). The following subtypes were defined using SEER's lymphoma
subtype recode, based on the International Lymphoma Epidemiology Consortium
(InterLymph) classification (21): DLBCL, follicular, marginal zone, peripheral T-cell, and
mantle cell lymphomas, mycosis fungoides/Sézary syndrome, other, specified NHL and
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NHL, not otherwise specified (NOS). We also defined Burkitt lymphoma (ICD-O-3 code
9687), and small lymphocytic lymphoma (9670), excluding Burkitt leukemia and chronic
lymphocytic leukemia, respectively, from these entities because lymphoid leukemias were
not considered part of NHL until the World Health Organization (WHO) classification was
introduced in 2000 (22). HIV status was not collected for cases of mycosis fungoides/Sézary
syndrome; thus, all cases were assumed to be HIV-uninfected in the analysis of total NHL.
CNS lymphoma (an AIDS-defining cancer) was not analyzed as a separate entity, as we
focused on histologically-defined NHL subtypes.
To calculate the denominator for NHL incidence rates in HIV-uninfected individuals, data
on HIV cases in each cancer registry area were obtained from CDC HIV surveillance data.
Since 1982, AIDS diagnoses have been uniformly reported to the CDC by registries in all 50
U.S. states and the District of Columbia. In 1994, CDC integrated national reporting of HIV
infection with AIDS case reporting. However, the uptake of HIV reporting was variable by
state; thus, data on all people living with HIV (with or without AIDS) only are available
during 2006–2009. For this analysis, the CDC estimated the number of people living with
AIDS from 1992–2009, and the number of people living with HIV infection from 2006–
2009 at the end of each calendar year in strata defined by calendar year, sex, attained age,
race/ethnicity and geographic area, with statistical adjustments made for reporting delays
(23, 24).
Statistical analysis
The proportions of NHL cases with HIV infection were estimated by NHL subtype and
stratified by sex, age group (0–14, 15–39, 40–59, 60+ year-olds), race/ethnicity (non-
Hispanic white, non-Hispanic black, Hispanic) and calendar period (1992–1995, 1996–1999,
2000–2004, 2005–2009). Incidence rates of HIV-uninfected NHL were estimated by
subtracting HIV-infected cases from the numerator and the AIDS population from the
denominator. We conducted a sensitivity analysis with data from 2006–2009 that compared
HIV-uninfected NHL rates calculated by removing all persons with HIV and only persons
with AIDS from the denominator. In an additional analysis, we assessed long-term trends in
U.S. NHL incidence rates with data from 8 SEER registries during 1974–2009 (Connecticut,
Hawaii, New Mexico, Utah, Atlanta, Detroit, Seattle/Puget Sound, San Francisco/Oakland).
All rates were age-standardized to the 2000 U.S. population and stratified by sex and age
group. Calendar trends in incidence rates were estimated overall and among HIV-uninfected
individuals, and annual percent changes in incidence rates were estimated with Joinpoint
regression (25, 26).
Results
Characteristics of HIV-infected and HIV-uninfected NHL cases
During 1992–2009, 115,643 persons were diagnosed with NHL in 605 million person-years.
Of these, 6,784 persons (5.9%) were HIV infected at the time of diagnosis. The majority of
HIV-infected NHL cases were AIDS-defining cancers: DLBCL (45.5%) and Burkitt
lymphoma (8.4%) (Table 1). Among HIV-uninfected NHL cases, DLBCL (33.6%) and
follicular lymphoma (17.9%) were the most common subtypes, and Burkitt lymphoma was
rare (1.4%). HIV-infected NHL cases predominantly occurred among males and 15–39 and
40–59 year-olds. A greater proportion of NHL cases were HIV-infected in the pre-HAART
calendar period (1992–1995) compared to the most recent calendar period (2004–2009).
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Proportion of NHL cases with HIV infection
The AIDS-defining NHL subtypes had the highest proportion of cases with HIV, with
26.9% of Burkitt lymphoma cases and 7.8% of DLBCL cases having HIV infection. In
addition, 3.2% of peripheral T-cell lymphoma cases and 11.6% of NHL NOS cases were
HIV-infected. The remaining NHL subtypes had very low proportions of cases with HIV
infection (0.7%–1.1%).
Within each NHL subtype, the proportion of NHL cases with HIV infection varied by sex,
age group, race/ethnicity and calendar period (Table 2). The proportion of NHL cases with
HIV infection was higher among males than females for total NHL (9.6% vs. 1.3%), as well
as all NHL subtypes, particularly DLBCL (12.8% vs. 1.6%), Burkitt lymphoma (32.9% vs.
9.0%) and peripheral T-cell lymphoma (4.5% vs. 1.3%). Among males, proportions of NHL
cases with HIV were highest among 15–39 (33.5%) and 40–59 (16.4%) year-olds, and very
low among 60+ (1.1%) and 0–14 year-olds (1.0%). Non-Hispanic black (21.7%) and
Hispanic men (17.6%) had higher proportions of HIV-infected NHL cases compared to non-
Hispanic white men (7.9%), and the proportion of HIV-infected NHL cases declined across
calendar periods (19.8% in 1992–1995, 5.5% in 2004–2009) in males. Patterns were similar
among females, though the proportions of NHL cases with HIV were much smaller.
Trends in overall NHL incidence rates
U.S. NHL rates nearly doubled during 1974–2009, increasing rapidly through the early
1990s, followed by more gradual increases and stable rates in recent years. In men, rates
increased through the early 1990s, and, in women, rates increased through the early 2000s
before stabilizing. Figure 1 shows NHL incidence rates prior to the onset of HIV in the U.S.
(1974–1979), during the first decade after the onset of the HIV epidemic (1980–1991), for
which HIV data are unavailable, and the most recent period (1992–2009), for which HIV
data are available overall and stratified by sex. During 1992–2009, NHL incidence rates in
the total population increased 0.3% per year. However, exclusion of HIV-infected cases
demonstrated that rates increased 1.4% per year through 2003 before flattening out (Figure
2A). The impact of HIV on NHL temporal trends was most pronounced in 15–39 and 40–59
year-olds. In the total population of 15–39 year-olds, NHL rates decreased during 1995–
1998, and then remained flat for the rest of the time period; however, among HIV-
uninfected individuals aged 15–39 years, rates increased 0.6% during 1992–2009. Among
40–59 year-olds, in the total population, NHL rates appeared to decline beginning in 1994,
but among HIV-uninfected individuals, rates continued to increase 0.9% per year through
2002 before stabilizing. HIV-infected NHL cases had little impact on rates among 60+ year-
olds; NHL rates in HIV-uninfected individuals became stable after increasing 1.7% per year
during 1992–2004 (Figure 2A). Notable differences in NHL incidence trends in the total
population and in HIV-uninfected individuals were primarily limited to men (data not
shown).
Trends in AIDS-defining NHL incidence rates
Incidence trends differed over time across NHL subtypes and by age group, with the impact
of HIV most evident for AIDS-defining NHLs. For DLBCL, rates in the total population
appeared to decline in 15–39 and 40–59 year-olds (Figure 2B; Table 3). However, rates
among HIV-uninfected individuals actually increased 0.9% per year during 1992–2009 for
15–39 year-olds and 2.1% per year during 1992–2002 before flattening out for 40–59 year-
olds. The differences in DLBCL rates in the total and HIV-uninfected populations for
individuals aged <60 years were more pronounced among men than women. For 60+ year-
olds, DLBCL rates also increased 2.9% per year during 1992–2004 before stabilizing, with
similar estimates in the total and HIV-uninfected populations.
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Burkitt lymphoma rates increased during 1992–2009 overall and among 15–39 and 40–59
year-olds in the total population; however, among HIV-uninfected individuals, rates
increased dramatically through 2000 overall and 2001 among 40–59 year-olds before
stabilizing. (Figure 2C; Table 3). Rates of HIV-uninfected Burkitt lymphoma in 60+ year-
olds reflected a similar pattern, stabilizing after increasing 19.8% per year during 1992–
2000.
Trends in non-AIDS-defining NHL incidence rates
HIV-infected NHL cases did not impact trends observed for the remaining subtypes, thus all
results below are for NHL in HIV-uninfected individuals. Among the more common B-cell
NHL subtypes, increases in follicular lymphoma rates of 2.3% per year were observed
through 2005 among 60+ year-olds, whereas rates were stable during the study period for
<60 year-olds (Figure 2D). Marginal zone lymphoma increased dramatically during 1992–
2001, before leveling off in subsequent years (Figure 2E; Table 3). A similar pattern was
observed for mantle cell lymphoma, with rates increasing 21.0% per year during 1992–1996
and 2.9% per year during 1996–2009 (Figure 2F; Table 3). In contrast, rates of small
lymphocytic lymphoma declined across all age groups (Figure 2G; Table 3).
Among T-cell NHLs, rates of peripheral T-cell lymphoma increased 10.9% per year until
1998 and at a more modest rate of 1.7% per year during 1998–2009 (Figure 2H; Table 3). In
the total population, rates of mycosis fungoides/Sézary syndrome increased through 1996
before stabilizing in subsequent years (data on HIV-uninfected rates were unavailable).
Throughout the study period, rates of other, specified NHLs increased across age groups,
particularly among 60+ year-olds (3.5% per year). In contrast, rates of NHL NOS declined
sharply during 1994–2002, and have been stable in subsequent years (Figures 2I & 2J).
Sensitivity analyses demonstrated that incidence rates calculated during 2006–2009 were
similar when all HIV-infected individuals were removed from the denominator compared
with our primary analysis, which removed only AIDS cases (Supplemental Table 1). In
addition, when we classified HIV status based on both the HIV indicator and cause of death,
we observed very similar NHL trends to our main analysis, and the proportion of NHL cases
with HIV increased slightly from 5.9% to 6.4% overall (10.4% in males and 1.4% in
females).
Discussion
Although some studies have reported stable NHL incidence rates in the U.S. in recent years
(8, 27), the status of the long-standing epidemic of NHL in the general population has been
uncertain because of the superimposition of NHL in persons with HIV over the past three
decades. By disentangling the incidence of NHL occurring in HIV-infected and HIV-
uninfected individuals, we have demonstrated for the first time that the general population
rates of NHL have stabilized since the early 2000s, independent of HIV.
Our results have several implications. First, the pre-HIV increase in NHL incidence rates, on
which the later HIV-associated increase in NHL incidence rates was added, has ended
without any discovery of its major causes. Many of the hypothesized contributors (9) have
been studied intensively, including medical history, anthropometric, lifestyle, dietary, sun
exposure, environmental and genetic risk factors (28). Several exposures, including
pesticides, hepatitis C virus, and certain chronic autoimmune conditions, do indeed appear to
elevate risk, but the low prevalence of these exposures in the general population indicate
little to no impact on trends. It is possible that other, unidentified infections may have arisen,
perhaps having powerful effects on NHL risk similar to what was observed for HIV.
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Our analysis also demonstrates that effective therapies for HIV, which have decreased NHL
risk in HIV-infected individuals (12, 14), have dramatically altered NHL trends in some
population groups. NHL rates in HIV-infected individuals declined rapidly in the early to
mid-1990s, followed by more gradual declines in more recent years (29). Though the
prevalence of HIV is low in the U.S. (0.4% in 2008 (30)), HIV has impacted NHL rates at
the national level and a large fraction of certain NHL subtypes in the U.S. occur among
HIV-infected individuals. In 10 regions of the U.S., the proportion of NHL cases with HIV
was greatest for NHL subtypes with the strongest associations with HIV [i.e., DLBCL
(7.8%) and Burkitt lymphoma (26.9%)] and in subgroups with higher HIV prevalence [i.e.,
men (9.6%), 15–39 and 40–59 year-olds (24.4% and 10.7%, respectively), and non-Hispanic
blacks and Hispanics (14.8% and 10.8%, respectively)]. Notably, the contribution of HIV-
infected cases to the total number of NHL cases has declined over time (1 out of 8 in 1992–
1995 to 1 out of 28 NHL cases in 2005–2009). Our results are similar to previously
published estimates for the U.S. during 1980–2007 based on data from the HIV/AIDS
Cancer Match Study (DLBCL: 9.4% in men and 0.93% in women; Burkitt lymphoma:
24.4% in men, 5.3% in women) (15). Of note, though not an AIDS-defining cancer, the
proportion of peripheral T-cell lymphoma cases with HIV infection was elevated compared
to the other subtypes. This is likely driven by the 24-fold elevated risk of peripheral T-cell
lymphoma in people with AIDS (31). The proportions of cases of other NHL subtypes with
HIV were low, due to weaker associations with HIV infection, and the proportion of cases of
NHL NOS with HIV infection was high, suggesting HIV-infected NHL cases are less likely
to be assigned a specific NHL subtype (1, 32).
Rates of DLBCL and follicular lymphoma, the two most common NHL subtypes, showed
similar trends among persons without HIV, despite possible differences in etiology (28).
Following years of increasing trends, DLBCL rates have been stable since 2003, and rates of
follicular lymphoma have been stable since 2005. For both DLBCL and follicular
lymphoma, rates have also been stable since the mid-2000s among 60+ year-olds, the group
with the largest burden of NHL.
We observed strong increases in peripheral T-cell, mantle cell, Burkitt and marginal zone
lymphomas, with rates stabilizing for Burkitt and marginal zone lymphomas in recent years.
The striking increases in the rates of marginal zone and mantle cell lymphomas have
previously been attributed to the adoption of a specific ICD-O-2 code for marginal zone
lymphoma by cancer registries, improved diagnosis of mantle cell lymphoma with
immunohistochemical staining, and increased recognition of these subtypes by pathologists
(32). Because of the rapid improvements in classification of NHL subtypes during the
1990s, increased incidence of rarer NHL subtypes during this time period should be
interpreted cautiously. In contrast, rates of small lymphocytic lymphoma have declined.
With the introduction of the WHO classification in 2000 (22), small lymphocytic lymphoma
and chronic lymphocytic leukemia were classified as a single entity, but changes in
diagnostic practices are unlikely to explain the decline in small lymphocytic lymphoma
because rates of chronic lymphocytic leukemia remained stable over the study period (data
not shown).
Rates of NHL, NOS decreased over time across age groups, indicating a pronounced period
effect likely due to increased diagnostic specificity introduced when the Revised European-
American Lymphoma (REAL) classification system was adopted in 1995, followed by the
WHO classification system (22, 32–34). As a result, the proportion of total NHLs that were
NOS declined from 31% in 1992-1995 to 13% in 2005-2009. It is possible that improved
classification of NHLs may have influenced rates of certain NHL subtypes (e.g., mantle cell
and marginal zone lymphomas as mentioned above). However, the rates of NHL NOS have
been stable since 2002; and thus likely had little impact on observed trends in NHL subtypes
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in recent years, and have had no impact on overall NHL rates. Additional efforts to increase
classification of NHLs could have important implications for monitoring and treatment,
particularly among HIV-infected individuals where 19% of NHLs were NOS in the most
recent time period.
An important strength of our study was the availability of data on the HIV status of
lymphoma cases diagnosed in 10 high-quality SEER registries. Though there may be some
misclassification due to the large proportion of NHL cases with unknown HIV status, one
prior study estimated that the SEER HIV flag has 97% sensitivity and 92% specificity at
identifying the HIV status of NHL cases, and another study reported that, compared to other
registry indicators of HIV status, the SEER HIV flag was positive in 91–95% of HIV-
infected NHL cases (19, 35). Further, the inclusion of NHL cases with HIV as a cause of
death in the HIV-infected group had little impact on our results. An additional limitation is
the lack of data on the number of HIV-infected individuals living in the registry areas during
the entire study period. As data on HIV infection were not uniformly collected by the CDC
in these regions until recently, in our main analysis we were only able to subtract out AIDS
cases from the populations at risk. In a sensitivity analysis limited to those calendar years
where HIV data were available for all registry areas, we showed that removal of all
individuals living with HIV resulted in very similar estimates.
Though the causes of the historic increase in general population NHL incidence rates remain
unknown, total NHL incidence rates in the U.S. have plateaued over the last 5–10 years, as
have the rates of several NHL subtypes, including DLBCL and follicular lymphoma,
independent of HIV. Continued monitoring of trends in NHL incidence among HIV-
uninfected people is critical to confirm the end of the long-standing NHL epidemic.
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Age-standardized incidence rates for NHL during 1974–2009 for 8 SEER registries: Atlanta,
Connecticut, Detroit, Hawaii, New Mexico, San Francisco-Oakland, Seattle-Puget Sound
and Utah. The black bars represent overall NHL incidence rates from the time period before
the HIV status indicator was available for a) men and women; b) men only; and c) women
only. The gray bars represent HIV-uninfected NHL cases and the white bars represent HIV-
infected NHL cases during the period when the HIV status indicator was available.
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Age-standardized incidence rates stratified by age group during 1992–2009 for a) NHL
overall; b) diffuse large B-cell lymphoma, c) Burkitt lymphoma, d) follicular lymphoma, e)
marginal zone lymphoma, f) mantle cell lymphoma, g) small lymphocytic lymphoma, h)
peripheral T-cell lymphoma, i) other, specified lymphomas and j) lymphoma, NOS. The
solid black line represents incidence rates in men overall, the dashed black line (----)
represents incidence rates in men without HIV infection, the larger dashed line (---)
represents incidence rates in women overall and the dotted line (......) represents incidence
rates in women without HIV infection.
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Table 1
Characteristics of HIV-uninfected and HIV-infected NHL cases in 10 SEER registries, 1992–2009.
HIV-uninfected HIV-infected
N % N %
Total 108,859 6,784
AIDS-defining NHLs
 DLBCL 36,607 33.6 3,089 45.5
 Burkitt lymphoma 1,540 1.4 568 8.4
Other NHL subtypes
 Follicular lymphoma 19,497 17.9 163 2.4
 Marginal zone lymphoma 8,514 7.8 96 1.4
 Small lymphocytic lymphoma 7,462 6.9 54 0.8
 Peripheral T-cell lymphoma 5,875 5.4 193 2.8
 Mantle cell lymphoma 3,602 3.3 24 0.4
 Mycosis fungoides/Sézary syndrome 3,446 3.2 --- ---
 Other, specified 3,146 2.9 75 1.1
 NOS 19,170 17.6 2,522 37.2
Sex
 Male 57,655 53.0 6,133 90.4
 Female 51,204 47.0 651 9.6
Age group, years
 0–14 1,193 1.1 15 0.2
 15–39 8,682 7.8 2,806 41.4
 40–59 28,622 26.3 3,427 50.5
 60+ 70,362 64.6 536 7.9
Race
 Non-Hispanic White 79,278 72.8 3,870 57.0
 Non-Hispanic Black 7,617 7.0 1,326 19.5
 Hispanic 11,347 10.4 1,370 20.2
 Other 10,617 9.8 218 3.2
Calendar period, average per year*
 1992–1995 4,934 4.5 671 9.9
 1996–1999 5,666 5.2 376 5.5
 2000–2004 6,361 5.8 263 3.9
*
The proportion of cases occurring in each calendar period was calculated per year, because the intervals do not include the same number of years
(i.e., 4 years in 1992–1995 and 1996– 1999 and 5 years in 2000–2004 and 2005–2009).
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Table 3
Joinpoint models of annual percent changes (APCs) in NHL trends excluding HIV-infected cases by sex, NHL
subtype and age group, 1992–2008
15–39 year-olds 40–59 year-olds 60+ year-olds Total
Years APC* Years APC* Years APC* Years APC*
Total NHL 1992–2009 0.6 (0.1, 1.0) 1992–2002 0.9 (0.2, 1.7) 1992–2004 1.7 (1.3, 2.0) 1992–2003 1.4 (1.1, 1.8)
2002–2009 −1.0 (−2.0, 0.1) 2004–2009 −0.7 (−1.9, 0.6) 2003–2009 −0.4 (−1.1, 0.4)
Diffuse large B-cell
lymphoma
1992–2009 0.9 (0.1, 1.7) 1992–2002 2.1 (0.9, 3.3) 1992–2004 2.9 (2.4, 3.5) 1992–2003 2.7 (2.1, 3.2)
2002–2009 −1.2 (−2.9, 0.4) 2004–2009 −1.7 (−3.4, 0.1) 2003–2009 −1.0 (−2.1, 0.2)
Burkitt lymphoma 1992–2009 4.9 (2.1, 7.9) 1992–2001 14.8 (5.9, 24.4) 1992–2000 19.8 (11.4, 28.8) 1992–2000 13.1 (8.0, 18.5)
2001–2009 −2.8 (−9.0, 3.7) 2000–2009 −0.6 (−4.0, 2.9) 2000–2009 −0.2 (−2.9, 2.6)
Follicular lymphoma 1992–2009 0.0 (−0.7, 0.8) 1992–2009 0.4 (−0.2, 0.9) 1992–2005 2.3 (1.7, 2.9) 1992–2005 1.7 (1.2, 2.1)
2005–2009 −2.1 (−5.2, 1.1) 2005–2009 −1.8 (−4.2, 0.7)
Marginal zone lymphoma 1992–1997 67.3 (28.1, 118.4) 1992–1996 91.6 (45.7, 152.1) 1992–1996 116.1 (62.1, 188.1) 1992–1996 99.9 (60.9, 148.3)
1997–2009 1.3 (−1.6, 4.2) 1996–2002 9.5 (3.4, 16.1) 1996–2009 4.7 (3.1, 6.3) 1996–2001 10.4 (2.2, 19.3)
2002–2009 0.7 (−2.0, 3.5) 2001–2009 2.0 (−0.1, 4.1)
Mantle cell lymphoma --- --- 1992–2009 2.6 (0.7, 4.5) 1992–1996 26.0 (13.0, 40.5) 1992–1996 21.0 (9.6, 33.7)
1996–2009 3.4 (2.2, 4.5) 1996–2009 2.9 (1.8, 4.0)
Small lymphocytic lymphoma 1992–2009 −4.5 (−7.2, −1.8) 1992–2009 −1.1 (−2.4, 0.3) 1992–2009 −0.9 (−1.6, −0.1) 1992–2009 −1.0 (−1.5, −0.4)
Peripheral T-cell lymphoma 1992–2009 4.9 (3.4, 6.3) 1992–1999 9.4 (2.7, 16.5) 1992–1996 17.3 (5.5, 30.5) 1992–1998 10.9 (6.2, 15.8)
1999–2009 −0.7 (−3.5, 2.2) 1996–2009 2.6 (1.3, 3.9) 1998–2009 1.7 (0.5, 3.0)
NHL, other specified 1992–2009 1.3 (−0.4, 3.1) 1992–2009 2.7 (0.7, 4.8) 1992–2009 3.5 (2.6, 4.4) 1992–2009 3.0 (2.2, 3.8)
NOS 1992–2009 −7.3 (−8.9, −5.6) 1992–2004 −9.0 (−10.6, −7.3) 1992–2002 −6.0 (−7.2, −4.8) 1992–1994 2.0 (−8.4, 13.7)
2004–2009 −0.5 (−8.4, 8.1) 2002–2009 −1.0 (−3.4, 1.5) 1994–2002 −8.2 (−9.6, −6.7)
2002–2009 −0.7 (−2.5, 1.1)
APC: annual percent change; CI: confidence interval; NHL: non-Hodgkin lymphoma
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